Takeda Sees Mainstays Tiding It Over Upcoming Expiries

Velcade First Up

As Takeda reported what its CEO described as "a remarkable year," the company sees itself as well positioned to ride out the expiries over the next few years of exclusivity for several big-selling products, as it looks to mainstays and more organic growth to tide it over the "temporary headwinds."

Takeda Tokyo HQ
Japan's biggest pharma firm expecting JPY1tn core operating profit • Source: Ian Haydock/Scrip

More from Japan

More from Focus On Asia